#ESMO26 Abstracts – Among ours | #Realworld stage III #melanoma outcomes following #neoadjuvant #nivolumab + #relatlimab or #nivolumab + #ipilimumab | To be presented by Mike Postow on behalf of this outstanding team in #Madrid #Spain | @MoffittNews https://t.co/s9wp2gDJRD https://t.co/S9w9gnGiQo